Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “ACROMEGALY”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,765 records · Page 98Linked to original sources
PubMed1980

Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status.

Administration of estrogens to acromegalic patients has been shown to reduce the serum concentrations of bioassayable somatomedin and to cause improvement in clinical status. These effects appear not to result from an effect on the secretion of growth hormone since growth hormone concentrations are not consistently reduced. Using a sensitive radioimmunoassay for somatomedin-C, we have assessed the relationship between the estrogen-induced reduction of somatomedin-C and changes in several indices of disease activity in five acromegalic patients. Statistically significant reductions in serum somatomedin-C (p < 0.02), urinary hydroxyproline (p < 0.05) and the phosphate clearance ratio (p < 0.01) occurred within three days of the institution of treatment with 1 mg ethynyl estradiol daily. Unlike the consistent reduction in serum somatomedin-C erratic changes in growth hormone were observed. The decline in serum somatomedin-C was not due to an estrogen-induced increase in somatomedin-binding proteins since total serum somatomedin-C concentrations measured after treatment of serum with acid also were reduced by estrogen therapy, and the magnitude of this reduction was equivalent to that observed in untreated serum. The study indicates that the reduction of immunoreactive somatomedin-C correlates with estrogen-induced improvement in the metabolic activity of acromegalic patients and suggests that measurement of somatomedin-C may be useful in monitoring the effects of other drugs on this disease.

Acromegaly↗
PubMed1985

Polyostotic fibrous dysplasia with acromegaly.

A 26-year-old man was found to have incomplete polyostotic fibrous dysplasia of bone and elevated growth hormone and prolactin levels. There was roentgenographic evidence of a pituitary tumor. The natural history of fibrous dysplasia in relationship to excess growth hormone secretion since childhood is described.

Acromegaly↗
PubMed1987

Radiographic determination of total lung capacity in patients with acromegaly.

Total lung capacity (TLC) was measured from posteroanterior and lateral chest radiographs by the ellipsoid (TLCE) and planimetric (TLCp) radiographic methods in 16 acromegalic patients. These measurements were compared to the TLC measured by body plethysmography (TLCBP) in order to investigate the accuracy of the two radiographic methods. Our results showed that the mean value of TLCBP was 6.52 +/- 1.51 litres (mean +/- SD) or 120 +/- 13.3% of predicted values, statistically significantly increased from normal values (P less than 0.001). The mean value of TLCE was 7.09 +/- 1.8 litres and did not differ from the mean value of TLCBP (P greater than 0.125). The mean value of TLCP was 7.74 +/- 1.20 litres, statistically significantly increased from TLCBP (P less than 0.005). A statistically highly significant linear relationship was found between TLCE and TLCBP (r = 0.867, P less than 0.001) identical to the line of identity. Similarly a highly significant linear relationship was found between TLCP and TLCBP (r = 0.793, P less than 0.001) but to the left of the line of identity. It is concluded that both the ellipsoid and planimetric radiographic methods could be used to measure TLC in acromegalic patients but the planimetric method needed the appropriate correction.

Acromegaly↗
PubMed1977

Improved tolerance to successive glucose loads in acromegaly.

The mechanism of the Staub-Traugott effect, or facilitated glucose disposal with closely timed successive glucose loads, remains poorly understood. Progressive suppression of growth hormone has been suggested as an explanation. To test this hypothesis, three successive intravenous glucose loads were administered to seven active acromegalic patients and six healthy controls. All subjects showed a clear Staub-Traugott effect despite failure of hyperglycemia to suppress abnormally high growth hormone levels in the acromegalics. Except for higher basal and incremental insulin release in the acromegalic patients, patterns of insulin secretion and suppression of free fatty acids were not substantially different from controls. These studies clearly suggest that hyperglycemia-induced suppression of growth hormone is not the cause of the Staub-Traugott effect.

Acromegaly↗